DiabetologNytt Nr 6-7/2026
Senaste Nr DiabetologNytt i PDF
Arkiv alla nyheter

Empa Lower CVD in 60+ T2DM. Diab care EMPRISE Study

Diabetes In Focus
Lower CV risk found with empagliflozin for older patients with type 2 diabetes

 

Empagliflozin has been shown to reduce the risk of major adverse cardiovascular events and heart failure hospitalizations in older adults with type 2 diabetes, according to a study published in Diabetes Care.

 

The study, based on Medicare data, compared empagliflozin with dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists, finding benefits across sociodemographic groups and baseline cardiovascular disease status.

 

Empagliflozin Lowers Cardiovascular Risk in Older Patients With Type 2 Diabetes

Publish Date November 11, 2026

 

In older adults with T2D, initiating empagliflozin reduces the risk of major adverse cardiovascular events and heart failure hospitalizations compared with dipeptidyl peptidase-4 inhibitors, highlighting the potential impact of increasing SGLT2 inhibitor use among older patients with CVD.

 

Empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, reduces cardiovascular risks across a broad range of older adults with type 2 diabetes (T2D), according to study findings published in Diabetes Care.

 

Empagliflozin and other SGLT2 inhibitors have been shown to have a variety of beneficial effects in people with T2D, including improved glycemic control and a reduction in cardiovascular events. Researchers examined whether the benefits of empagliflozin vary across sociodemographic subgroups and by the presence of cardiovascular disease (CVD) at baseline.

 

This analysis was based on the EMPRISE study, which contained Medicare fee-for-service claims data spanning from August 2014 to December 2020. Using a new-user, active comparator design, the researchers compared outcomes of adults 65 years and older who had T2D and started taking empagliflozin with those of people initiating either a dipeptidyl peptidase-4 inhibitor (DPP4i) or a glucagon-like peptide-1 receptor agonist (GLP-1 RA), type 1 diabetes (T1D), gestational, or secondary diabetes; end-stage kidney disease; HIV/AIDS; solid organ transplants; cancer; or nursing home admission at baseline.

 

After propensity score matching, there were 71,763 pairs of patients taking either empagliflozin or a DPP4i (mean age, 72.6 vs 72.5 years; 47.6% women) and 89,732 pairs taking either empagliflozin or a GLP-1 RA (mean age, 72.46 vs 72.45; 49.2% women). Baseline CVD was present in 51.2% and 50.6% of patients in the respective cohorts.

 

Multiple studies have shown lower rates of SGLT2i use by older individuals and those with established CVD compared with the general population with T2D. Given the greater absolute benefits of empagliflozin in these populations, addressing these observed disparities in medication use would be expected to have an outsized public health impact.

 

The most common DPP4is were sitagliptin (76%) and linagliptin (20%), whereas the most frequently used GLP-1 RAs were dulaglutide (44%), liraglutide (24%), and semaglutide (19%).

 

Over a mean follow-up of approximately 10 months, compared with DPP4is, empagliflozin was associated

 

with lower rates of major adverse cardiovascular events (MACE; myocardial infarction, stroke, or all-cause mortality),

 

with a hazard ratio (HR) of 0.77 (99.9% CI, 0.69-0.85)

 

heart failure hospitalization (HR, 0.72; 99.9% CI, 0.67-0.79),

 

and all-cause mortality (HR, 0.66; 99.9% CI, 0.57-0.76).

 

Incidence rate differences (IRDs) were -10.3 (99.9% CI, -14.1 to -6.4), -18.3 (99.9% CI, -22.9 to -13.6), and -8.6 (99.9% CI, -11.4 to -5.8) events per 1000 person-years, respectively.

 

There were greater absolute benefits of empagliflozin versus DPP4is for those with baseline CVD based on the IRD scale, but there was a greater relative reduction in heart failure hospitalization for those without established CVD.

 

Compared with patients starting a GLP-1 RA, those initiating empagliflozin carried a lower risk of heart failure hospitalization, with an HR of 0.88 (99.9% CI, 0.81-0.95) and an IRD of -6.9 (99.9% CI, -10.8 to -3.1) per 1000 person-years; rates of MACE and all-cause mortality did not differ between groups.

 

The results were generally consistent across subgroups defined by age, sex, race and ethnicity, socioeconomic factors, and baseline CVD, albeit with greater absolute benefits in patients with higher baseline risks

Study limitations include the observational design, the lack of self-reported race and ethnicity in Medicare data, limited use of newer GLP-1 RAsduring the study period, lack of statistical power in some smaller subgroups, and the possibility of residual confounding.

 

The study authors concluded, “Multiple studies have shown lower rates of SGLT2i use by older individuals and those with established CVD compared with the general population with T2D. Given the greater absolute benefits of empagliflozin in these populations, addressing these observed disparities in medication use would be expected to have an outsized public health impact.”

 

Disclosure: The study was supported by Boehringer Ingelheim.

References:
Cromer SJ, Tesfaye H, Cho H, et al. Effects of empagliflozin on cardiovascular outcomes are consistent across sociodemographic subgroups: A real-world analysis from the EMPRISE study. Diabetes Care. Published online September 21, 2026. doi:10.2337/dca26-0039
https://diabetesjournals.org/care/article-abstract/doi/10.2337/dca26-0039/172555/Effects-of-

 

Empagliflozin-on-Cardiovascular?redirectedFrom=fulltext#xd_co_f=MjllMjkxYmYtMTcwNy00ODUyLWFiYTUtMzFmZTk4YWY4MGYy~

 

 

ABSTRACt
Effects of Empagliflozin on Cardiovascular Outcomes Are Consistent Across Sociodemographic Subgroups: A Real-World Analysis From the EMPRISE Study

 

Author
Helen Tesfaye et al

OBJECTIVE
We aimed to explore the heterogeneity of empagliflozin treatment effects on major adverse cardiovascular events (MACE), hospitalization for heart failure (HHF), and all-cause mortality (ACM) across sociodemographic and cardiovascular disease (CVD) subgroups of adults with type 2 diabetes (T2D).

 

RESEARCH DESIGN AND METHODS
Using 2014–2020 Medicare claims data, we examined rates of MACE (e.g., composite myocardial infarction, stroke, all-cause mortality [ACM]), HHF, and ACM among propensity score–matched individuals aged ≥65 years with T2D initiating empagliflozin compared with those prescribed dipeptidyl peptidase-4 inhibitors (DPP4is) and those prescribed GLP-1 receptor agonists (GLP-1RAs). We calculated hazard ratios (HRs) and incidence rate differences (IRDs) overall and by age, sex, race or ethnicity, socioeconomic factors, and baseline CVD.

 

RESULTS
Empagliflozin was associated with decreased risk of MACE (HR 0.77, 99.9% CI [0.69, 0.85]; IRD = −10.3 [−14.1, −6.4]); HHF (HR 0.72 [0.67, 0.79]; IRD = −18.3 [−22.9, −13.6]); and ACM (HR 0.66 [0.57, 0.76]; IRD = −8.6 [−11.4, −5.8]) compared with DPP4is. Effect heterogeneity by baseline CVD was present across all outcomes on the IRD scale but only for HHF on the HR scale. Empagliflozin was also associated with decreased risk of HHF (HR 0.88 [0.81, 0.95]; IRD = −6.9 [−10.8, −3.1]) versus GLP-1RAs, with effect heterogeneity by baseline CVD on the IRD scale. No effect heterogeneity was observed by sociodemographic factors, although a numeric trend suggested greater absolute benefit in patients aged ≥75 years compared with those aged 65–74 years.

 

CONCLUSIONS
Empagliflozin reduced cardiovascular events across sociodemographic and CVD subgroups compared with both DPP4is and GLP-1RAs, with higher absolute benefits observed in those with prevalent CVD

 

Medicinsk kommentar  Detta är en observationsstudie. Ändå värdefullt med in real life effekt signifikant vid T2DM äldre patienter

 

Nyhetsinfo

www red DiabetologNytt

Facebook
LinkedIn
Email
WhatsApp